TITLE

Indication creep: physician beware

AUTHOR(S)
Hébert, Paul C.; Stanbrook, Matthew
PUB. DATE
September 2007
SOURCE
CMAJ: Canadian Medical Association Journal;9/25/2007, Vol. 177 Issue 7, p697
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article offers the author's comments on the off-label use of a drug called erythropoietin in the treatment of critically ill patients in the U.S. He states that the treatment may potentially result in thrombotic complications. He asserts that the treatment can be effective when physicians with understanding of the appropriate evidence, and clinical experience determine its usage. He further refers to the role of erythropoietin manufacturers in promoting widespread off-label usage.
ACCESSION #
26592253

 

Related Articles

  • Off-label use of erythropoietin may be harmful, doctors told. Spurgeon, David // BMJ: British Medical Journal (International Edition);9/15/2007, Vol. 335 Issue 7619, p532 

    This article reports on a caution issued by the Canadian Medical Association (CMA) on the off-label use of erythropoietin to treat anaemia in critically ill patients. The CMA says the caution is based on a meta-analysis in its journal which suggests that treatment of patients on dialysis, those...

  • Epidemiology of severe sepsis in the intensive care unit. Vincent, Jean-Louis; Atalan, Hakan Korkut // British Journal of Hospital Medicine (17508460);Aug2008, Vol. 69 Issue 8, p442 

    The article examines the various studies on epidemiology of severe sepsis in the intensive care unit (ICU). Two key considerations in reviewing the published epidemiological data of sepsis in the ICU are presented, including admission and length of stay, and the scope size of the study....

  • Gastrointestinal Complications in Critically Ill Patients: The Intensivists' Overview. Gottlieb, Jonathan E.; Menashe, Phillip I.; Cruz, Edwin // American Journal of Gastroenterology;Apr1986, Vol. 81 Issue 4, p227 

    The critical care environment may be characterized by invasive monitoring, vasoactive drugs, and major interventions which may have adverse effects on gastrointestinal function. Furthermore, conditions such as heart failure or sepsis may compromise oxygen delivery to gastrointestinal organs....

  • Focus on optimization of early antimicrobial therapy in ICU-acquired infections. Timsit, Jean-François; Paiva, José-Artur; Bassetti, Matteo // Intensive Care Medicine;Nov2016, Vol. 42 Issue 11, p1658 

    The article focuses on the optimization of antimicrobial therapy in intensive care unit-acquired infections. Topics include an overview on the development of antimicrobial therapy which seeks to deliver appropriating medical treatment while limiting antibiotic selection pressure and resistance,...

  • Influenza treatment with oseltamivir outside of labeled recommendations. MCQUADE, BRIANNA; BLAIR, MELISSA // American Journal of Health-System Pharmacy;1/15/2015, Vol. 72 Issue 2, p112 

    Purpose: Published evidence regarding the use of the antiinfluenza agent oseltamivir outside of the standard dosing recommendations is reviewed. Summary: Oseltamivir is a neuraminidase inhibitor indicated for the treatment of uncomplicated influenza in patients two weeks of age or older who have...

  • CME/CNE Questions.  // Critical Care Alert;Dec2007, Vol. 15 Issue 9, p71 

    A quiz about the administration of erythropoietin to critically ill patients is presented.

  • Speak Out. Wright, David; Avallone, Anthony N.; Berger, Aaron; Wrenn, John // Urology Times;4/1/2009, Vol. 37 Issue 4, p30 

    The article presents answers to a question on whether pharmaceutical companies be allowed to market pharmaceutical products for off-label use.

  • Off-Label Drug Uses. . Generali, Joyce A.; Cada, Dennis J. // Hospital Pharmacy;Mar2010, Vol. 45 Issue 3, p208 

    This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This...

  • SLEEPING PILLS. Hanau, Michael S. // Primary Psychiatry;May2008, Vol. 15 Issue 5, p23 

    A letter to the editor is presented in response to an article by Milton K. Erman which critiques the popularity of trazodone and other non-benzodiazepine analogs for off-label use.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics